BCL2 and breast carcinoma: There was significant co-expression of TFF3 and BCl2 in breast carcinoma cases treated with neoadjuvant therapy (p = 0.0152) suggesting anti-apoptotic role of TFF3 (Fig. 7b and 8c), (Additional file 1: Table S2).